EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Metabolic dysfunction‐associated steatotic liver disease, insulin sensitivity and continuous glucose monitoring metrics in patients with type 1 diabetes: A multi‐centre cross‐sectional study

Michela Vergani, Nicolò Diego Borella, Mariangela Rizzo, Matteo Conti, Silvia Perra, Eleonora Bianconi, Elena Sani, Alessandro Csermely, Elisabetta Grespan, Giovanni Targher iD, Gianluca Perseghin iD, Alessandro Mantovani iD und 1 weitere

Diabetes, Obesity and Metabolism · 2025-06 · 27 (6) · 3201-3211

DOI: 10.1111/dom.16333 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 13.03.2025. Verfasst von Michela Vergani und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Rehabilitation, Policlinico di Monza, Monza, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin Resistance, Liver Cirrhosis, Fatty Liver. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aim We assessed the prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) and significant liver fibrosis in adults with type 1 diabetes mellitus (T1DM) and the association of MASLD with insulin sensitivity and continuous glucose monitoring metrics.

Methods

We consecutively enrolled 198 adults with T1DM undergoing vibration‐controlled transient elastography with liver stiffness measurement (LSM) and controlled attenuation parameter (CAP). All participants had a continuous glucose monitoring (CGM) device. Insulin sensitivity was evaluated by estimated glucose disposal rate (eGDR). MASLD was defined as CAP ≥ 248 db/m and the presence of at least one cardiometabolic risk factor. Significant liver fibrosis was defined as LSM ≥ 7 kPa.

Results

Patients had a mean age of 56 years, mean BMI of 26.0 ± 5.9 kg/m 2 , and mean eGDR of 7.1 ± 2.3 mg/kg/min. 73 (37%) patients had MASLD (using a CAP threshold of 274 dB/m), 16 (8.1%) of whom had significant liver fibrosis. MASLD was associated with a significantly lower eGDR (beta coefficient = −0.367, 95% confidence interval −0.472 to −0.261; p < 0.001). This association remained significant, even after adjustment for age, sex, body mass index, plasma triglycerides, diabetes duration, daily insulin dose, time above the range of glucose levels, LSM and chronic kidney disease. No association was observed between MASLD and CGM‐derived metrics. These results were not different when we used a CAP threshold of 274 dB/m for diagnosing MASLD.

Conclusion

In T1DM, MASLD was inversely associated with eGDR and biomarkers of insulin resistance but not with CGM‐derived metrics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Insulin ResistanceLiver CirrhosisFatty LiverHumansMaleFemaleMiddle AgedCross-Sectional StudiesAdultBlood GlucoseBlood Glucose Self-MonitoringElasticity Imaging TechniquesPrevalenceContinuous Glucose Monitoring

Stichwörter der Autor:innen

CAPCMGFibroscanMASLDeGDRestimated glucose disposal ratehepatic steatosisinsulin resistancemetabolic dysfunction‐associated steatotic liver diseasetype 1 diabetes

Substanzen

Blood Glucose

Autor:innen und Institutionen

  • Department of Medicine and Rehabilitation, Policlinico di Monza, Monza, Italy.
  • School of Medicine and Surgery, University of Milano Bicocca, Milan, Italy.
  • Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
  • Department of Medicine, University of Verona, Verona, Italy.
  • Metabolic Diseases Research Unit, IRCCS Sacro Cuore-Don Calabria Hospital, Negrar di Valpolicella (VR), Italy.

ORCID-Profile: Giovanni Targher, Gianluca Perseghin, Alessandro Mantovani, Stefano Ciardullo

Zitieren

APA

Vergani, M., Borella, N. D., Rizzo, M., Conti, M., Perra, S., Bianconi, E., Sani, E., Csermely, A., Grespan, E., Targher, G., Perseghin, G., Mantovani, A., & Ciardullo, S. (2025). Metabolic dysfunction‐associated steatotic liver disease, insulin sensitivity and continuous glucose monitoring metrics in patients with type 1 diabetes: A multi‐centre cross‐sectional study. Diabetes, Obesity and Metabolism, 27(6), 3201-3211. https://doi.org/10.1111/dom.16333

Vancouver

Vergani M, Borella ND, Rizzo M, Conti M, Perra S, Bianconi E, et al. Metabolic dysfunction‐associated steatotic liver disease, insulin sensitivity and continuous glucose monitoring metrics in patients with type 1 diabetes: A multi‐centre cross‐sectional study. Diabetes, Obesity and Metabolism. 2025;27(6):3201-3211. doi:10.1111/dom.16333

BibTeX
@article{Vergani2025,
  author = {Vergani, Michela and Borella, Nicolò Diego and Rizzo, Mariangela and Conti, Matteo and Perra, Silvia and Bianconi, Eleonora and Sani, Elena and Csermely, Alessandro and Grespan, Elisabetta and Targher, Giovanni and Perseghin, Gianluca and Mantovani, Alessandro and Ciardullo, Stefano},
  title = {Metabolic dysfunction‐associated steatotic liver disease, insulin sensitivity and continuous glucose monitoring metrics in patients with type 1 diabetes: A multi‐centre cross‐sectional study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {6},
  pages = {3201--3211},
  doi = {10.1111/dom.16333}
}
Kostenlos starten →